RXDX 105

Drug Profile

RXDX 105

Alternative Names: AC013773; CEP-32496; RXDX-105

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Ambit Biosciences Corporation; Cephalon
  • Developer Ignyta; Teva Pharmaceutical Industries
  • Class Antineoplastics; Isoxazoles; Phenyl ethers; Phenylurea compounds; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Feb 2017 Ignyta initiates an expanded access to RXDX 105 for Cancer in USA before February 2017 (NCT03052569)
  • 01 Dec 2016 Interim efficacy and adverse events data from phase Ib part of the phase I/Ib trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
  • 15 Nov 2016 Updated adverse events data from phase Ib part of the phase I/Ib trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top